Treatment News : Sovaldi & Ribavirin Is Effective for HIV/HCV Population

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2014

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 24, 2014

Sovaldi & Ribavirin Is Effective for HIV/HCV Population

CROI 2014In a study of people coinfected with hepatitis C virus (HCV) and HIV, Gilead Sciences’ recently approved Sovaldi (sofosbuvir) and ribavirin cured 75 percent of those with genotype 1, aidsmap reports. While cure rates for genotype 2 were higher, they were diminished for genotype 3, which under current treatment guidelines has replaced genotype 1 as the most difficult to treat genotype. Results from the open-label Phase III PHOTON-1 trial of the NS5B polymerase inhibitor Sovaldi plus ribavirin were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

A total of 114 treatment-naive coinfected people with genotype 1, 4 percent of whom had cirrhosis, received Sovaldi and ribavirin for 24 weeks. Another 68 treatment-naive participants and 41 treatment-experienced participants with genotypes 2 or 3 also received the regimen, but for varying lengths of time: Those who had not been treated before received only 12 weeks of treatment while prior non-responders were treated for 24 weeks. Twenty-four percent of the genotype 2 and 3 group had cirrhosis.

Over 90 percent of the study population was taking antiretrovirals for HIV. The average CD4 count was higher than 600.

Seventy-five percent of the genotype 1 group achieved a sustained virologic response 24 weeks after completing therapy (SVR24, considered a cure). Eighty-eight percent of the treatment-naive genotype 2 participants were cured. Treatment-naive genotype 3s did not fare as well, however: Only 67 percent achieved an SVR24. Treatment-experienced genotype 2s and 3s had respective cure rates of 92 percent and 94 percent.

The regimen was generally safe and well tolerated. Thirteen people experienced serious side effects, with seven of them stopping therapy as a result. The most common side effects were fatigue, insomnia, headache and nausea.

To read the aidsmap story, click here. ‘

To watch a webcast of the CROI presentation, click here.

Search: Sovaldi, ribavirin, sofosbuvir, Gildead Sciences, HIV, hepatitis C, virus, hep C, HCV, Conference on Retroviruses and Opportunistic Infections, CROI.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dambitious
    Gone
    New York


    InDefaultOf
    Seattle
    Washington


    max38man
    Chicago
    Illinois


    blaze11212
    brooklyn
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.